English Court Rules Against Lilly in Alimta Vitamin Dosage Regimen Patent Lawsuit
The English court ruled that Alimta's vitamin dosage regimen patent would not be infringed by a generic competitor that had stated its intent to market certain alternative salt forms of pemetrexed in the
The compound patents for Alimta in major European countries remain in force and are expected to provide exclusivity through 2015. In a parallel infringement case on one of the alternative salt forms of pemetrexed earlier this year, the
"We strongly disagree with the ruling by the
Harrington continued, "Although Alimta's compound patents remain in force and are expected to provide exclusivity in major European countries through 2015, we continue to believe that Alimta's vitamin dosage regimen patents would be infringed by the entry of generic pemetrexed in
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. C-LLY
This release contains forward-looking statements regarding the Alimta patent litigation. These statements are based on management's current expectations but actual results may differ materially. There can be no assurance that the company will prevail in any appeal. Also, the company cannot predict whether generic pemetrexed will be marketed prior to the resolution of this litigation. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the
_____________________________________
Alimta® (pemetrexed, Lilly)
Logo- http://photos.prnewswire.com/prnh/20031219/LLYLOGO
Refer to: |
(317) 276-5795 - |
(317) 655-6874 - |
SOURCE
News Provided by Acquire Media